US12138235B2 - Cape-loaded targeted microvesicular cancer drug and method for developing the same - Google Patents

Cape-loaded targeted microvesicular cancer drug and method for developing the same Download PDF

Info

Publication number
US12138235B2
US12138235B2 US17/840,700 US202217840700A US12138235B2 US 12138235 B2 US12138235 B2 US 12138235B2 US 202217840700 A US202217840700 A US 202217840700A US 12138235 B2 US12138235 B2 US 12138235B2
Authority
US
United States
Prior art keywords
cape
cells
solution
microvesicles
loaded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/840,700
Other versions
US20220362194A1 (en
Inventor
Fikrettin Sahin
Pakize Neslihan TASLI
Oguz Kaan KIRBAS
Ezgi AVSAR APDIK
Huseyin APDIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeditepe Universitesi
Original Assignee
Yeditepe Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeditepe Universitesi filed Critical Yeditepe Universitesi
Priority to US17/840,700 priority Critical patent/US12138235B2/en
Assigned to YEDITEPE UNIVERSITESI reassignment YEDITEPE UNIVERSITESI ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: APDIK, Huseyin, AVSAR APDIK, Ezgi, SAHIN, FIKRETTIN, KIRBAS, Oguz Kaan, TASLI, Pakize Neslihan
Publication of US20220362194A1 publication Critical patent/US20220362194A1/en
Application granted granted Critical
Publication of US12138235B2 publication Critical patent/US12138235B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes

Definitions

  • the present invention relates to production of a drug which is specific for SH-SY5Y neuroblastoma cancer by loading CAPE to microvesicles that the specialized skin cell leaves into the medium.
  • CAPE caffeic acid phenethyl ester
  • CAPE has antioxidant, antineoplastic, antitumoral and cytoprotective effects.
  • CAPE inhibits carcinogenesis, cell cycle and metastasis, and induces apoptosis [1].
  • antibiotics streptomycin, vancomycin, isoniazid, ethambutol
  • cancer drugs mitomycin, doxorubicin, cisplatin, methotrexate
  • CAPE (40 ⁇ M) dose-dependently stops cell proliferation, induces cell cycle arrest and apoptosis, and suppresses angiogenesis in estrogen receptor positive (ER+) MCF-7, estrogen receptor negative (ER ⁇ ) MDA-MB-231, and triple negative (ER ⁇ , PR ⁇ , HER2 ⁇ ) TNBC breast cancer cell lines [3]. Additionally, it has also been determined that CAPE (40 ⁇ M) inhibits proliferation of breast cancer stem cells [4]. It has been shown that CAPE dose-dependently inhibits cell proliferation in LNCaP, DU-145 and PC-3 prostate cancer cell lines and Akt signaling pathway [5].
  • CAPE (50 ⁇ M) prevents proliferation by inducing S and G2/M phase cell cycle arrests and induces apoptosis in the cells in ME180 cervical cancer cell lines [6]. It was determined that CAPE (100 ⁇ M) treatment decreased G1 phase cell population, increased G2/M phase cell population and induced apoptosis in the cells by inhibiting the Akt signaling pathway in TW2.6 oral squamous cell carcinoma cell line [7].
  • CAPE treatment decreased radiation induced lung injury in rats [14].
  • CAPE was applied in the range of 4-20 ⁇ M, but no effect was observed in the SH-SY5Y cells [15].
  • CAPE methoxy poly(ethylene glycol)-b-poly( ⁇ -caprolactone) copolymer
  • the objective of the present invention is to provide a cell-specific targeted vesicle development by loading CAPE to the microvesicles obtained as a result of the culturing and subsequent specialization (differentiation) of the tissue cells.
  • Another objective of the invention is to use CAPE at lower concentrations compared to the state-of-the-art applications to minimize its toxicity to both the cells other than the targeted cells and the body.
  • FIG. 1 is a graphical representation of the combinations formed by loading CAPE to the microvesicles obtained from SH-SY5Y, PC3 and PNT-1 cells on cell viability of SH-SY5Y cells in an application of 48 hours.
  • CAPE Caffeic Acid Phenethyl Ester
  • MV Microvesicle
  • * P ⁇ 0.05
  • FIG. 2 is a graphical representation of the effect of the combinations obtained by loading different doses of CAPE (caffeic acid phenethyl ester) to the microvesicles obtained from the cells, which are differentiated from stem cells into healthy nerve cells, on cell viability of SH-SY5Y cells in an application of 48 hours.
  • CAPE Caffeic Acid Phenethyl Ester
  • MV Microvesicle
  • * P ⁇ 0.05
  • the invention is a cancer drug obtained by loading drug (CAPE) into the microvesicles produced by the differentiated skin stem cells, and it is applied due to the cytotoxic effect of these cellular vesicles on cancer cells.
  • the drug is loaded to the vesicles of the cells, which are specialized by being treated with growth factors applied to provide nerve cell properties.
  • the cells which are differentiated by administering a Neurobasal solution preferably containing 10 ng/ml bFGF, 10 ng/ml EGF, 1% B7 supplement, 1% ITS (insulin, transferrin and selenium), 10% Glutamine and 1% PSA for 12-14 days; are provided with new properties by this method rendering the vesicles to target the SHSY5Y cancer cells.
  • the cellular vesicles are loaded with CAPE thereby acquiring the feature of specifically recognizing the SHSY5Y cancer cells.
  • cytotoxic property is provided to the cellular vesicles which are produced by changing the factors such as the temperature of 37° C., pH, 5% carbon dioxide and the DMEM, F12, RPMI media that enable cell growth, in addition to the growth conditions of the cells (stem cells, cell lines, primer cells, cancer cells, cells obtained from tissues).
  • CAE caffeic acid phenethyl ester
  • cytotoxic property is provided to the cellular vesicles which are produced by treating the cells (stem cells, cell lines, primer cells, cancer cells, cells obtained from tissues) with other chemicals (growth factors such as bFGF, EGF, NGF; hormones such as melatonin, insulin, lactoferrin; vitamins such as ascorbic acid, folic acid; and minerals such as calcium, magnesium, boron) in addition to the cells' own growth conditions.
  • growth factors such as bFGF, EGF, NGF
  • hormones such as melatonin, insulin, lactoferrin
  • vitamins such as ascorbic acid, folic acid
  • minerals such as calcium, magnesium, boron
  • these vesicles which are collected from the stem cells differentiated into nerve cells, while demonstrating a nerve cell recognition feature, they also exhibit cytotoxicity specific to SHSY5Y after treatment for 12-14 days as seen in FIG. 1 .
  • the term “specialized” is given as a result of the comparison of the SHSY5Y cell with the other cells as seen in FIG. 1 .
  • the microvesicles which are produced by the cells specific to a particular cancer type by means of the differentiation of the cells to the tissue cells, where the said tumor formation is observed, acquired on the 12-14th days rather than 25-30 days; are used. Accordingly, the microvesicles produced by the cells are used because the specific characteristics of SHSY5Y cells, which are acquired by differentiation of the stem cells subjected to nerve cell differentiation, are carried in the early stage of nerve differentiation by differentiation at 12-14 days rather than 25-30 days.
  • CAPE loading at a concentration of 5 ⁇ M to 100 ⁇ M is performed to the cellular microvesicles produced via the nerve cells; and these values are far more advantageous over the toxic high amounts of >100 ⁇ M applied in the previous individual CAPE applications in the literature.
  • the cancer drug product which is produced by the CAPE loaded specialized cellular microvesicles obtained in the scope of the invention, has no toxic effect on healthy cells and other cell lines, while showing toxic effect only on a specific type of cancer. As shown in FIG. 1 , and as mentioned above, the specialized microvesicles show cytotoxic effect only on SHSY5Y cells.
  • CAPE loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer comprises the steps of
  • the skin stem cell, SH-SY5Y, PNT-1A, PC-3 cells are cultured preferably in DMEM (Dulbecco's Modified Eagle's Medium) medium containing 10% fetal bovine serum and 1% PSA in cell culture incubators preferably at 37° C. and 5% CO 2 .
  • DMEM Dulbecco's Modified Eagle's Medium
  • a Neurobasal solution preferably containing 10 ng/ml bFGF, 10 ng/ml EGF, 1% B7 supplement, 1% ITS (insulin, transferrin and selenium), 10% Glutamine and 1% PSA is prepared and then the specialization protocol is applied by administering this specialization solution to the cells seeded in 6-well cell culture plates once in two days for 12 to 14 days.
  • the step of preparing the stock solution 45.75 mg of CAPE is preferably dissolved in 3.22 mL of DMSO (Dimethyl sulfoxide). The final concentration obtained is approximately 50,000 ⁇ M.
  • DMSO Dimethyl sulfoxide
  • the solution collected from the culture medium is centrifuged at 300 g for 10 minutes to remove the waste cells.
  • the supernatant remaining at the upper part of the tube after the centrifugation is transferred to a new tube and it is centrifuged at 14,000 g for 30 minutes in order to remove possible cell components.
  • the supernatant remaining at the upper part of the tube after the centrifugation is transferred to a new tube and 1 ⁇ 2 volume of the kit buffer solution (solution A) is added, and it is incubated for one day at +4 degrees.
  • loading CAPE into the microvescular structure is carried out by incubation at room temperature.
  • Microvesicle solution is added to a 50 ⁇ M CAPE solution preferably prepared in 2 ml of PBS such that the final concentration will be 100 ⁇ g/ml, and the mixture is incubated for 20 minutes at room temperature (25° C.).
  • the precipitation process is carried out using the isolation kit to obtain the substance-loaded vesicles.
  • the resulting substance-loaded pellet is dissolved in distilled water (dH 2 O).
  • the skin stem cells, PNT-1A, PC-3 and SH-SY5Y cells are used.
  • the toxicity of the targeted microvesicles, which are obtained by specialization of the stem cells, to the SH-SY5Y cells was observed.
  • the skin stem cells, SH-SY5Y, PNT-1A and PC-3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Invitrogen) and 1% PSA (Biological Industries, Beit Haemek, Israel) at a temperature of 37° C. in cell culture incubators with 5% CO 2 .
  • DMEM Dulbecco's modified Eagle's medium
  • PSA Biological Industries, Beit Haemek, Israel
  • the cells in the culture solution reaching sufficient confluence are seeded in 6-well culture plates and the specialization protocol is applied thereon for 13 days with Neurobasal solution containing 10 ng/ml bFGF, 10 ng/ml EGF, 1% B7 supplement, 1% ITS (insulin, transferrin, and selenium), 10% Glutamine and 1% PSA by changing the media every other day.
  • Neurobasal solution containing 10 ng/ml bFGF, 10 ng/ml EGF, 1% B7 supplement, 1% ITS (insulin, transferrin, and selenium), 10% Glutamine and 1% PSA by changing the media every other day.
  • the process of preparing the stock solution is started.
  • 45.75 mg of CAPE is dissolved in 3.22 mL of DMSO (Dimethyl sulfoxide).
  • the final concentration obtained is 50,000 ⁇ M.
  • Microvesicles are isolated from the skin cells on which specialization protocol is applied.
  • EX01 Exo-spinTM kit was used for microvesicle isolation from the specialized skin cells in the scope of the invention.
  • the medium collected from the culture medium is centrifuged at 300 g for 10 minutes in order to remove the waste cells.
  • the supernatant is transferred to a new tube, and it is centrifuged at 14,000 g for 30 minutes in order to remove possible cell components.
  • the supernatant obtained by this centrifugation is transferred to a new tube and 1 ⁇ 2 volume of the kit buffer solution (solution A) is added, and it is incubated for one day at +4 degrees.
  • CAPE which is prepared as a separate solution
  • Loading of CAPE, which is prepared as a separate solution, into the microvesicles is carried out at room temperature.
  • a solution of 50 ⁇ M CAPE prepared in 2 ml PBS is added the microvesicle solution such that the final concentration will be 100 ug/ml.
  • the mixture is incubated for 20 minutes at room temperature (25° C.) and then, the precipitation process is carried out using the isolation kit to obtain CAPE loaded vesicles.
  • the resulting substance-loaded pellet is dissolved in distilled water (dH 2 O).
  • the amount of CAPE transferred into the microvesicular structure was performed based on the spectrophotometric measurement method.
  • the intrinsic radiation of the molecule at 323 nm wavelength was utilized.
  • Different concentrations (1-100 ⁇ M) of CAPE were measured at the wavelength of 323 nm to form a standard curve.
  • the amount of CAPE that was loaded was determined using two interrelated methods. Firstly, the amount of CAPE that was loaded was determined by measuring the amount remaining in the supernatant after precipitation of the CAPE-loaded microvesicles. Secondly, it was determined by fractionation of the membrane structures of the microvesicles loaded with the precipitated substance, and measurement of the amount of CAPE loaded to the vesicular structure.
  • DMEM Dulbecco's modified Eagle's medium
  • PSA Biological Industries, Beit Haemek, Israel
  • Cell viability was determined by using 3-(4,5-di-methyl-thiazol-2-yl)-5-(3-carboxy-methoxy-phenethyl)-2-(4-sulfo-phenethyl)-2H-tetrazolium (MTS)-method (CellTiter96 AqueousOne Solution; Promega, Southampton, UK). 10 ⁇ l MTS solution was added onto the cells within a 100 ⁇ l medium and it was incubated at 37° C. in dark for 2 hours. After the incubation process, cell viability was observed by performing absorbance measurement via ELISA plate reader (Biotek, Winooski, VT) device at 490 nm wavelength.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method of producing a caffeic acid phenethyl ester loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer. The method includes seeding a plurality of skin stem cells in a medium; enabling the plurality of skin stem cells in the medium to reach a confluency of 70-80% to be seeded in a plurality of culture plates; preparing a caffeic acid phenethyl ester stock solution by dissolving the caffeic acid phenethyl ester in dimethyl sulfoxide DMSO; performing a microvesicle isolation from specialized skin cells; adding the caffeic acid phenethyl ester into a plurality of microvesicles; and separating the caffeic acid phenethyl ester loaded microvesicles from the caffeic acid phenethyl ester which is free in the solution and not loaded to a microvesicle.

Description

CROSS-REFERENCE TO THE RELATED APPLICATIONS
This application is a divisional application of U.S. patent application Ser. No. 16/955,087, filed on Jun. 18, 2020, which is the national stage entry of International Application No. PCT/TR2018/050816, filed on Dec. 17, 2018, which is based upon and claims priority to Turkish Patent Application No. 2017/20642, filed on Dec. 18, 2017, the entire contents of which are incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to production of a drug which is specific for SH-SY5Y neuroblastoma cancer by loading CAPE to microvesicles that the specialized skin cell leaves into the medium.
BACKGROUND
CAPE (caffeic acid phenethyl ester) is one of the most widely studied active components of poplar type propolis. CAPE has antioxidant, antineoplastic, antitumoral and cytoprotective effects. CAPE inhibits carcinogenesis, cell cycle and metastasis, and induces apoptosis [1]. One of the interesting and important effects of CAPE is that when used with various antibiotics (streptomycin, vancomycin, isoniazid, ethambutol) and cancer drugs (mitomycin, doxorubicin, cisplatin, methotrexate); it reduces the toxicity occurring dependent on the said drugs [2].
It has been shown that CAPE (40 μM) dose-dependently stops cell proliferation, induces cell cycle arrest and apoptosis, and suppresses angiogenesis in estrogen receptor positive (ER+) MCF-7, estrogen receptor negative (ER−) MDA-MB-231, and triple negative (ER−, PR−, HER2−) TNBC breast cancer cell lines [3]. Additionally, it has also been determined that CAPE (40 μM) inhibits proliferation of breast cancer stem cells [4]. It has been shown that CAPE dose-dependently inhibits cell proliferation in LNCaP, DU-145 and PC-3 prostate cancer cell lines and Akt signaling pathway [5]. It has been demonstrated that CAPE (50 μM) prevents proliferation by inducing S and G2/M phase cell cycle arrests and induces apoptosis in the cells in ME180 cervical cancer cell lines [6]. It was determined that CAPE (100 μM) treatment decreased G1 phase cell population, increased G2/M phase cell population and induced apoptosis in the cells by inhibiting the Akt signaling pathway in TW2.6 oral squamous cell carcinoma cell line [7]. It has been determined that in the SK-1 Hep1 liver cancer cell line, to which combined treatment of CAPE (30 μg/ml) and TRAIL was applied, caspase activation increased, cell death receptors were activated via JNK and p38 signaling pathways and apoptosis was induced in the cells [8]. In the experimental studies, it was observed that CAPE inhibited the toxicity occurring during chemotherapy and radiotherapy. It is reported that the prophylactic administration of CAPE prevented the damage caused by doxorubicin in the tissues of kidney [9], heart [10] and brain [11], and the liver damage depending on administration of cisplatin [12] and tamoxifen [13] in rats. It has also been shown that CAPE treatment decreased radiation induced lung injury in rats [14]. In the study conducted with CAPE in SH-SY5Y neuroblastoma cell line, CAPE was applied in the range of 4-20 μM, but no effect was observed in the SH-SY5Y cells [15].
In another study, CAPE (100 μg/ml) was loaded in methoxy poly(ethylene glycol)-b-poly(ε-caprolactone) (CE) copolymer and it was applied in CT26 colon carcinoma cell line. When the results were compared with unaccompanied application of CAPE, no difference was observed on the effects thereof on cell proliferation and death [16].
The problems encountered in the state-of-the-art applications can be listed as follows:
    • Not being specific to the cell and tissue.
    • Requirement to be used at high concentrations.
    • Activation of mononuclear phagocyte system.
    • Cancerous tissues showing chemical resistance in drug applications.
SUMMARY
The objective of the present invention is to provide a cell-specific targeted vesicle development by loading CAPE to the microvesicles obtained as a result of the culturing and subsequent specialization (differentiation) of the tissue cells.
Another objective of the invention is to use CAPE at lower concentrations compared to the state-of-the-art applications to minimize its toxicity to both the cells other than the targeted cells and the body.
BRIEF DESCRIPTION OF THE DRAWINGS
“Development of a CAPE loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer” developed to fulfill the objectives of the present invention is illustrated in the accompanying figures, in which:
FIG. 1 is a graphical representation of the combinations formed by loading CAPE to the microvesicles obtained from SH-SY5Y, PC3 and PNT-1 cells on cell viability of SH-SY5Y cells in an application of 48 hours. (CAPE: Caffeic Acid Phenethyl Ester, MV: Microvesicle, *: P<0.05)
FIG. 2 is a graphical representation of the effect of the combinations obtained by loading different doses of CAPE (caffeic acid phenethyl ester) to the microvesicles obtained from the cells, which are differentiated from stem cells into healthy nerve cells, on cell viability of SH-SY5Y cells in an application of 48 hours. (CAPE: Caffeic Acid Phenethyl Ester, MV: Microvesicle, *: P<0.05)
 DETAILED DESCRIPTION OF THE EMBODIMENTS
The invention is a cancer drug obtained by loading drug (CAPE) into the microvesicles produced by the differentiated skin stem cells, and it is applied due to the cytotoxic effect of these cellular vesicles on cancer cells. The drug is loaded to the vesicles of the cells, which are specialized by being treated with growth factors applied to provide nerve cell properties. Within the scope of the invention, the cells; which are differentiated by administering a Neurobasal solution preferably containing 10 ng/ml bFGF, 10 ng/ml EGF, 1% B7 supplement, 1% ITS (insulin, transferrin and selenium), 10% Glutamine and 1% PSA for 12-14 days; are provided with new properties by this method rendering the vesicles to target the SHSY5Y cancer cells. By means of the invention, the cellular vesicles are loaded with CAPE thereby acquiring the feature of specifically recognizing the SHSY5Y cancer cells.
There are two embodiments within the scope of the invention. In the first embodiment; by means of drug (CAPE (caffeic acid phenethyl ester) loading, cytotoxic property is provided to the cellular vesicles which are produced by changing the factors such as the temperature of 37° C., pH, 5% carbon dioxide and the DMEM, F12, RPMI media that enable cell growth, in addition to the growth conditions of the cells (stem cells, cell lines, primer cells, cancer cells, cells obtained from tissues). In the second embodiment; by means of drug (CAPE (caffeic acid phenethyl ester) loading, cytotoxic property is provided to the cellular vesicles which are produced by treating the cells (stem cells, cell lines, primer cells, cancer cells, cells obtained from tissues) with other chemicals (growth factors such as bFGF, EGF, NGF; hormones such as melatonin, insulin, lactoferrin; vitamins such as ascorbic acid, folic acid; and minerals such as calcium, magnesium, boron) in addition to the cells' own growth conditions. It has been observed that these vesicles, which are collected from the stem cells differentiated into nerve cells, while demonstrating a nerve cell recognition feature, they also exhibit cytotoxicity specific to SHSY5Y after treatment for 12-14 days as seen in FIG. 1 . The term “specialized” is given as a result of the comparison of the SHSY5Y cell with the other cells as seen in FIG. 1 .
In one embodiment of the invention, the microvesicles; which are produced by the cells specific to a particular cancer type by means of the differentiation of the cells to the tissue cells, where the said tumor formation is observed, acquired on the 12-14th days rather than 25-30 days; are used. Accordingly, the microvesicles produced by the cells are used because the specific characteristics of SHSY5Y cells, which are acquired by differentiation of the stem cells subjected to nerve cell differentiation, are carried in the early stage of nerve differentiation by differentiation at 12-14 days rather than 25-30 days.
In one embodiment of the invention, with the purpose of developing a CAPE loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer, CAPE loading at a concentration of 5 μM to 100 μM is performed to the cellular microvesicles produced via the nerve cells; and these values are far more advantageous over the toxic high amounts of >100 μM applied in the previous individual CAPE applications in the literature.
The cancer drug product, which is produced by the CAPE loaded specialized cellular microvesicles obtained in the scope of the invention, has no toxic effect on healthy cells and other cell lines, while showing toxic effect only on a specific type of cancer. As shown in FIG. 1 , and as mentioned above, the specialized microvesicles show cytotoxic effect only on SHSY5Y cells.
The inventive development of CAPE loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer comprises the steps of
    • Seeding (culturing) skin stem cells in a medium,
    • Implementing the specialization protocol, which enables the cells in a culture medium reaching sufficient confluency (70-80%) to be seeded in 6-well cell culture plates whereby the feature of neuroblastoma recognition is provided to the cells enabling them to become targeted,
    • Dissolving CAPE (caffeic acid phenethyl ester) in DMSO (Dimethyl sulfoxide) thereby preparing the stock solution (thus different concentrations can be obtained from the more concentrated stock solution),
    • Performing microvesicle isolation from the specialized skin cells,
    • Adding CAPE into the microvesicles,
    • Separating the CAPE loaded microvesicles from the CAPE which is free in the solution and not loaded to a microvesicle,
    • Obtaining the CAPE loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer which is the final product.
In the preferred embodiment of the invention, during the step of carrying out the culturing of the skin stem cells; the skin stem cell, SH-SY5Y, PNT-1A, PC-3 cells are cultured preferably in DMEM (Dulbecco's Modified Eagle's Medium) medium containing 10% fetal bovine serum and 1% PSA in cell culture incubators preferably at 37° C. and 5% CO2.
In the preferred embodiment of the invention, during the step of specializing the cells in the culture medium, a Neurobasal solution preferably containing 10 ng/ml bFGF, 10 ng/ml EGF, 1% B7 supplement, 1% ITS (insulin, transferrin and selenium), 10% Glutamine and 1% PSA is prepared and then the specialization protocol is applied by administering this specialization solution to the cells seeded in 6-well cell culture plates once in two days for 12 to 14 days.
In the preferred embodiment of the invention, in the step of preparing the stock solution, 45.75 mg of CAPE is preferably dissolved in 3.22 mL of DMSO (Dimethyl sulfoxide). The final concentration obtained is approximately 50,000 μM.
In the preferred embodiment of the invention, in the step of microvesicle isolation from the specialized skin cells, the solution collected from the culture medium is centrifuged at 300 g for 10 minutes to remove the waste cells. The supernatant remaining at the upper part of the tube after the centrifugation is transferred to a new tube and it is centrifuged at 14,000 g for 30 minutes in order to remove possible cell components. The supernatant remaining at the upper part of the tube after the centrifugation is transferred to a new tube and ½ volume of the kit buffer solution (solution A) is added, and it is incubated for one day at +4 degrees. The next day, after it is centrifuged at 16,000 g for 1 hour, the pellet is dissolved in distilled water (dH2O).
In the preferred embodiment of the invention, loading CAPE into the microvescular structure is carried out by incubation at room temperature. Microvesicle solution is added to a 50 μM CAPE solution preferably prepared in 2 ml of PBS such that the final concentration will be 100 μg/ml, and the mixture is incubated for 20 minutes at room temperature (25° C.). Then, the precipitation process is carried out using the isolation kit to obtain the substance-loaded vesicles. The resulting substance-loaded pellet is dissolved in distilled water (dH2O).
In the “CAPE loaded microvascular cancer drug targeting SHSY5Y neuroblastoma cancer (Micro-CAPE)” of the present invention, the skin stem cells, PNT-1A, PC-3 and SH-SY5Y cells are used. The toxicity of the targeted microvesicles, which are obtained by specialization of the stem cells, to the SH-SY5Y cells was observed. By loading CAPE to the microvesicles obtained in this study, a cell-specific targeted vesicle is developed while the toxicity to both the other cells and the body is minimized by using much lower concentrations of CAPE compared to the concentrations previously used in the literature.
Within the scope of the invention, first of all, the skin stem cells, SH-SY5Y, PNT-1A and PC-3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Invitrogen) and 1% PSA (Biological Industries, Beit Haemek, Israel) at a temperature of 37° C. in cell culture incubators with 5% CO2. The cells in the culture solution reaching sufficient confluence (70-80%) are seeded in 6-well culture plates and the specialization protocol is applied thereon for 13 days with Neurobasal solution containing 10 ng/ml bFGF, 10 ng/ml EGF, 1% B7 supplement, 1% ITS (insulin, transferrin, and selenium), 10% Glutamine and 1% PSA by changing the media every other day. In the meantime, the process of preparing the stock solution is started. For this purpose, 45.75 mg of CAPE is dissolved in 3.22 mL of DMSO (Dimethyl sulfoxide). The final concentration obtained is 50,000 μM.
Microvesicles are isolated from the skin cells on which specialization protocol is applied. EX01 Exo-spin™ kit was used for microvesicle isolation from the specialized skin cells in the scope of the invention. The medium collected from the culture medium is centrifuged at 300 g for 10 minutes in order to remove the waste cells. The supernatant is transferred to a new tube, and it is centrifuged at 14,000 g for 30 minutes in order to remove possible cell components. The supernatant obtained by this centrifugation is transferred to a new tube and ½ volume of the kit buffer solution (solution A) is added, and it is incubated for one day at +4 degrees. The next day, after it is centrifuged at 16,000 g for 1 hour, the pellet is dissolved in distilled water (dH2O).
Loading of CAPE, which is prepared as a separate solution, into the microvesicles is carried out at room temperature. To a solution of 50 μM CAPE prepared in 2 ml PBS is added the microvesicle solution such that the final concentration will be 100 ug/ml. The mixture is incubated for 20 minutes at room temperature (25° C.) and then, the precipitation process is carried out using the isolation kit to obtain CAPE loaded vesicles. The resulting substance-loaded pellet is dissolved in distilled water (dH2O).
By means of the inventive “Development of CAPE loaded microvesicular cancer drug targeting SHSY5Y neuroblastoma cancer (Micro-CAPE)”, the drug is enabled
    • to be used at much lower concentrations (5 μM),
    • to be specific to cell type,
    • to pass the blood-brain barrier,
    • not to cause inflammation,
    • not to have any toxicity to the body,
    • to prevent resistance of the cancer type,
    • to be metabolized in the cell after use,
    • to remain in the circulation for a long time.
Experimental Studies
Measuring the Amount of CAPE that is Loaded
After the loading process, measurement of the amount of CAPE transferred into the microvesicular structure was performed based on the spectrophotometric measurement method. When measuring the amount of CAPE that was loaded, the intrinsic radiation of the molecule at 323 nm wavelength was utilized. Different concentrations (1-100 μM) of CAPE were measured at the wavelength of 323 nm to form a standard curve. The amount of CAPE that was loaded was determined using two interrelated methods. Firstly, the amount of CAPE that was loaded was determined by measuring the amount remaining in the supernatant after precipitation of the CAPE-loaded microvesicles. Secondly, it was determined by fractionation of the membrane structures of the microvesicles loaded with the precipitated substance, and measurement of the amount of CAPE loaded to the vesicular structure.
Determining Toxicity
After the cells were seeded in 96-well culture plates (Corning Glasswork, Corning, N.Y.) at 5000 cells/well in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Invitrogen) and 1% PSA (Biological Industries, Beit Haemek, Israel) in the culture solution, the viability levels of the cells were measured on day 1, 2 and 3. Cell viability was determined by using 3-(4,5-di-methyl-thiazol-2-yl)-5-(3-carboxy-methoxy-phenethyl)-2-(4-sulfo-phenethyl)-2H-tetrazolium (MTS)-method (CellTiter96 AqueousOne Solution; Promega, Southampton, UK). 10 μl MTS solution was added onto the cells within a 100 μl medium and it was incubated at 37° C. in dark for 2 hours. After the incubation process, cell viability was observed by performing absorbance measurement via ELISA plate reader (Biotek, Winooski, VT) device at 490 nm wavelength.
REFERENCES
  • [1]. Lin, H. P., Lin, C. Y., Liu, C. C., Su, L. C., Huo, C., Kuo, Y. Y., Tseng, J. C., Hsu, J. M., Chen, C. K., Chuu, C. P. 2013. “Caffeic Acid phenethyl ester as a potential treatment for advanced prostate cancer targeting akt signaling”, Int J Mol Sci., 6; 14(3):5264-83. doi: 10.3390/ijms14035264.
  • [2]. Tolba, M. F., Omar, H. A., Azab, S. S., Khalifa, A. E., Abdel-Naim, A. B., Abdel-Rahman, S. Z. 2014. “Caffeic acid phenethyl ester: A review of its antioxidant activity, protective effects against ischemia-reperfusion injury and drug adverse reactions”, Crit Rev Food Sci Nutr., DOI: 10.1080/10408398.2013.821967.
  • [3]. Wu, J., Omene, C., Karkoszka, J., Bosland, M., Eckard, J., Klein, C. B., Frenkel, K. 2011. “Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer”, Cancer Lett., 1; 308(1):43-53. doi: 10.1016/j.canlet.2011.04.012.
  • [4]. Omene, C. O., Wu, J., Frenkel, K. 2012. “Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells”, Invest New Drugs, 30(4):1279-88. doi: 10.1007/s10637-011-9667-8.
  • [5]. Chuu, C. P., Lin, H. P., Ciaccio, M. F., Kokontis, J. M., Hause, R. J. Jr, Hiipakka, R. A., Liao, S., Jones, R. B. 2012. “Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks”, Cancer Prev Res (Phila)., 5(5):788-97. doi: 10.1158/1940-6207.CAPR-12-0004-T.
  • [6]. Hsu, T. H., Chu, C. C., Hung, M. W., Lee, H. J., Hsu, H. J., Chang, T. C. 2013. “Caffeic acid phenethyl ester induces E2F-1-mediated growth inhibition and cell-cycle arrest in human cervical cancer cells” FEBS J., 280(11):2581-93. doi: 10.1111/febs.12242.
  • [7]. Kuo, Y. Y., Lin, H. P., Huo, C., Su, L. C., Yang, J., Hsiao, P. H., Chiang, H. C., Chung, C. J., Wang, H. D., Chang, J. Y., Chen, Y. W., Chuu, C. P. 2013. “Caffeic Acid Phenethyl Ester Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of Akt Signaling”, Int J Mol Sci., 24; 14(5):8801-17. doi: 10.3390/ijms14058801.
  • [8]. Kim, E. Y., Ryu, J. H., Kim, A. K. 2013. “CAPE promotes TRAIL-induced apoptosis through the upregulation of TRAIL receptors via activation of p38 and suppression of JNK in SK-Hep1 hepatocellular carcinoma cells”, Int J Oncol., 43(4):1291-300. doi: 10.3892/ijo.2013.2018.
  • [9]. Yagmurca, M., Erdogan, H., Iraz, M., Songur, A., Ucar, M., Fadillioglu, E. 2004. “Caffeic acid phenethyl ester as a protective agent against doxorubicin nephrotoxicity in rats”, Clin Chim Acta, 348:27-34.
  • [10]. Fadillioglu, E., Oztas, E., Erdogan, H., Yagmurca, M., Sogut, S., Ucar, M., et al. 2004. “Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats”, J Appl Toxicol, 24:47-52.
  • [11]. Irmak, M. K., Fadillioglu, E., Sogut, S., Erdogan, H., Gulec, M., Ozer, M., et al. 2003. “Effects of caffeic acid phenethyl ester and alpha-tocopherol on reperfusion injury in rat brain”, Cell Biochem Funct., 21:283-9.
  • [12]. Iraz, M., Ozerol, E., Gulec, M., Tasdemir, S., Idiz, N., Fadillioglu, E., et al. 2006. “Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat”, Cell Biochem Funct, 24:357-61.
  • [13]. Akyol, S., Ginis, Z., Armutcu, F., Ozturk, G., Yigitoglu, M. R., Akyol, O. 2012. “The potential usage of caffeic acid phenethyl ester (CAPE) against chemotherapy-induced and radiotherapy-induced toxicity”, Cell Biochem Funct., 30(5):438-43. doi: 10.1002/cbf.2817.
  • [14]. Yildiz, O. G., Soyuer, S., Saraymen, R., Eroglu, C. 2008. “Protective effects of caffeic acid phenethyl ester on radiation induced lung injury in rats”, Clin Invest Med, 31: E242-7.
  • [15]. Izuta, H., Shimazawa, M., Tazawa, S., Araki, Y., Mishima, S., & Hara, H. 2008. “Protective effects of Chinese propolis and its component, chrysin, against neuronal cell death via inhibition of mitochondrial apoptosis pathway in SH-SY5Y cells”, Journal of Agricultural and Food Chemistry, 56(19), 8944-8953.
  • [16]. Lee, H. Y., Jeong, Y. I., Kim, E. J., Lee, K. D., Choi, S. H., Kim, Y. J., . . . & Choi, K. C. 2015. “Preparation of Caffeic Acid Phenethyl Ester-Incorporated Nanoparticles and Their Biological Activity”. Journal of pharmaceutical sciences, 104(1), 144-154.

Claims (11)

What is claimed is:
1. A method of producing a composition comprising caffeic acid phenethyl ester (CAPE) loaded microvesicles for targeting inhibition of SH-SY5Y neuroblastoma cancer growth, the method comprising the steps of:
A) seeding a plurality of skin stem cells in a culture medium,
B) implementing a specialization protocol to obtain a plurality of specialized skin cells, wherein the specialization protocol enables the plurality of skin stem cells in the culture medium reaching a confluency of 70-80% to be seeded in a plurality of 6-well cell culture plates whereby a feature of neuroblastoma recognition is provided to the plurality of skin stem cells enabling the plurality of skin stem cells to become targeted,
C) preparing a CAPE stock solution by dissolving the CAPE in dimethyl sulfoxide (DMSO),
D) performing a microvesicle isolation from the plurality of specialized skin cells to obtain a plurality of microvesicles,
E) adding the CAPE into the plurality of microvesicles,
F) separating a plurality of CAPE loaded microvesicles from the CAPE that is free in the CAPE stock solution and not loaded to the plurality of microvesicles,
G) obtaining the CAPE loaded microvesicles as a final product.
2. The method according to claim 1, wherein during step A, the plurality of skin stem cells are cultured in DMEM containing 10% fetal bovine serum, and 1% PSA in a plurality of cell culture incubators at a temperature of 37° C. and 5% CO2, and the plurality of skin stem cells are at least one selected from the group consisting of SH-SY5Y cells, PNT-1A cells and PC-3 cells.
3. The method according to claim 1, wherein step B comprises:
preparing a specialization solution, wherein the specialization solution is a Neurobasal solution containing 10 ng/ml bFGF, 10 ng/ml EGF, 1% B7 supplement, 1% insulin, transferrin, and selenium (ITS), 10% Glutamine and 1% PSA, and implementing the specialization protocol by administering the specialization solution to the plurality of skin stem cells seeded in the plurality of 6-well cell culture plates once every two days for 12 to 14 days.
4. The method according to claim 1, wherein step C comprises preparing the CAPE stock solution with a final concentration of approximately 50,000 μM by dissolving 45.75 mg of the CAPE in 3.22 mL of DMSO.
5. The method according to claim 1, wherein step D comprises a first centrifugation, wherein a solution collected from the culture medium is centrifuged at 300 g for 10 minutes to remove a plurality of waste cells.
6. The method according to claim 5, wherein step D further comprises a second centrifugation, wherein a supernatant remaining at an upper part of a centrifuge tube after the first centrifugation is transferred to a new centrifuge tube, and the supernatant remaining is centrifuged at 14,000 g for 30 minutes in order to remove a plurality of possible cell components.
7. The method according to claim 5, wherein step D further comprises an incubation, wherein a supernatant remaining at an upper part of a tube after the first centrifugation is transferred to a new tube and ½ volume of a buffer solution is added, and the supernatant remaining is incubated for one day at +4 degrees Celsius.
8. The method according to claim 7, wherein following 1 day of the incubation, after the supernatant remaining is centrifuged at 16,000 g for 1 hour, and a pellet is dissolved in distilled water.
9. The method according to claim 1, wherein in step E, the CAPE loading into the plurality of microvesicles is carried out by incubation at room temperature.
10. The method according to claim 9, wherein in step E comprises preparing a 50 μM CAPE solution in 2 mL PBS, and adding a solution of the plurality of microvesicles to the 50 μM CAPE solution prepared in 2 ml of PBS to obtain a mixture such that a final concentration of the mixture is 100 μg/ml, and then incubating the mixture for 20 minutes at the room temperature.
11. The method according to claim 10, wherein step F comprises performing a precipitation to the mixture incubated formed in step E to obtain the plurality of CAPE loaded microvesicles.
US17/840,700 2017-12-18 2022-06-15 Cape-loaded targeted microvesicular cancer drug and method for developing the same Active 2039-06-02 US12138235B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/840,700 US12138235B2 (en) 2017-12-18 2022-06-15 Cape-loaded targeted microvesicular cancer drug and method for developing the same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
TR2017/20642 2017-12-18
TR2017/20642A TR201720642A2 (en) 2017-12-18 2017-12-18 GUIDED CAFE LOADED MICROVESICULAR CANCER DRUG AND METHOD OF ITS IMPROVEMENT
PCT/TR2018/050816 WO2019132831A2 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same
US202016955087A 2020-06-18 2020-06-18
US17/840,700 US12138235B2 (en) 2017-12-18 2022-06-15 Cape-loaded targeted microvesicular cancer drug and method for developing the same

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/TR2018/050816 Division WO2019132831A2 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same
US16/955,087 Division US11510891B2 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same

Publications (2)

Publication Number Publication Date
US20220362194A1 US20220362194A1 (en) 2022-11-17
US12138235B2 true US12138235B2 (en) 2024-11-12

Family

ID=67066521

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/955,087 Active 2039-04-24 US11510891B2 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same
US17/840,700 Active 2039-06-02 US12138235B2 (en) 2017-12-18 2022-06-15 Cape-loaded targeted microvesicular cancer drug and method for developing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/955,087 Active 2039-04-24 US11510891B2 (en) 2017-12-18 2018-12-17 Cape-loaded targeted micro vesicular cancer drug and method for developing the same

Country Status (8)

Country Link
US (2) US11510891B2 (en)
EP (1) EP3727590A4 (en)
JP (1) JP7509423B2 (en)
CN (1) CN112020380A (en)
AU (1) AU2018395740B2 (en)
CA (1) CA3086056A1 (en)
TR (1) TR201720642A2 (en)
WO (1) WO2019132831A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201720642A2 (en) * 2017-12-18 2019-07-22 Univ Yeditepe GUIDED CAFE LOADED MICROVESICULAR CANCER DRUG AND METHOD OF ITS IMPROVEMENT
KR102132457B1 (en) * 2019-05-10 2020-07-09 주식회사 바이오솔루션 Cell culture medium for culturing extracellular vesicles at a high concentration and a method for making conditioned medium containing a high level of extracellular vesicles using the cell culture medium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209499A1 (en) * 2014-07-18 2017-07-27 Manuka Health New Zealand Limited Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health
WO2019132831A2 (en) * 2017-12-18 2019-07-04 Yeditepe Universitesi Cape-loaded targeted micro vesicular cancer drug and method for developing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932517A3 (en) * 2006-12-11 2008-07-16 Universiteit Utrecht Holding B.V. Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof
NZ586497A (en) * 2008-01-04 2012-07-27 Lydac Neuroscience Ltd Microvesicles
US20140127316A1 (en) * 2011-05-20 2014-05-08 New York University Propolis and caffeic acid phenethyl ester and uses thereof
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
AU2014251388B2 (en) * 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles
CN106692984B (en) * 2016-12-08 2020-02-18 武汉大学 A tumor-targeted delivery carrier based on cell-derived microvesicles and its preparation method and application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170209499A1 (en) * 2014-07-18 2017-07-27 Manuka Health New Zealand Limited Propolis and Extracts Thereof for the Treatment of Skin Cancers and Improvement of Skin Health
WO2019132831A2 (en) * 2017-12-18 2019-07-04 Yeditepe Universitesi Cape-loaded targeted micro vesicular cancer drug and method for developing the same
US20210023038A1 (en) * 2017-12-18 2021-01-28 Yeditepe Universitesi Cape-loaded targeted micro vesicular cancer drug and method for developing the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Adelaide Fernandes et al. "Secretome from SH-SY5Y APPSwe cells trigger time-dependent CHME3 microglia activation phenotypes, ultimately leading to miR-21 exosome shuttling." Biochimie, vol. 155, 2018, pp. 67-82. (Year: 2018). *
Elisa Lazaro-Ibanez et al. "Different gDNA Content in the Subpopulations of Prostate Cancer Extracellular Vesicles: Apoptotic Bodies, Microvesicles, and Exosomes." The Prostate, vol. 74, 2014, pp. 1379-1390. (Year: 2014). *
Google Patents. Abstract of Turkish Patent TR 201720642 A2. Obtained by examiner from https://patents.google.com/patent/TR201720642A2/en?oq=TR+2017%2f20642 on Aug. 1, 2024. Originally published on Jul. 22, 2019, 3 printed pages. (Year: 2019). *
Heikki Saari et al. "Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells." Journal of Controlled Release, vol. 220, 2015, pp. 727-737. (Year: 2015). *
Hyo-Young Lee et al. "Preparation of Caffeic Acid Phenethyl Ester-Incorporated Nanoparticles and Their Biological Activity." Journal of Pharmaceutical Sciences, vol. 104, 2015, pp. 144-154. (Year: 2015). *

Also Published As

Publication number Publication date
JP2021508320A (en) 2021-03-04
WO2019132831A2 (en) 2019-07-04
US20210023038A1 (en) 2021-01-28
US11510891B2 (en) 2022-11-29
WO2019132831A3 (en) 2019-09-26
EP3727590A2 (en) 2020-10-28
CN112020380A (en) 2020-12-01
TR201720642A2 (en) 2019-07-22
RU2020123531A (en) 2022-01-20
AU2018395740B2 (en) 2024-02-15
AU2018395740A1 (en) 2020-07-09
US20220362194A1 (en) 2022-11-17
EP3727590A4 (en) 2021-09-29
JP7509423B2 (en) 2024-07-02
CA3086056A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
McCubrey et al. Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
US12138235B2 (en) Cape-loaded targeted microvesicular cancer drug and method for developing the same
Hung et al. Oxidative and endoplasmic reticulum stress signaling are involved in dehydrocostuslactone-mediated apoptosis in human non-small cell lung cancer cells
Zhao et al. Inotodiol inhabits proliferation and induces apoptosis through modulating expression of cyclinE, p27, bcl-2, and bax in human cervical cancer HeLa cells
EP3034076B1 (en) Combined application of isothiocyanate compound and anti-cancer medicine
Becit et al. Interaction of curcumin on cisplatin cytotoxicity in HeLa and HepG2 carcinoma cells
El-Ela et al. Promising cardioprotective effect of baicalin in doxorubicin-induced cardiotoxicity through targeting toll-like receptor 4/nuclear factor-κB and Wnt/β-catenin pathways
Del Bubba et al. Vaccinium myrtillus L. extract and its native polyphenol‐recombined mixture have anti‐proliferative and pro‐apoptotic effects on human prostate cancer cell lines
Wang et al. Total saponins from Tupistra chinensis baker inhibits growth of human gastric cancer cells in vitro and in vivo
RU2785400C2 (en) Anticancer drug in form of cape-loaded micro-vesicles of directed action and its development method
He et al. Housefly (Musca domestica) larvae powder, preventing oxidative stress injury via regulation of UCP4 and CyclinD1 and modulation of JNK and P38 signaling in APP/PS1 mice
KR102317222B1 (en) Composition for preventing, improving or treating colorectal cancer comprising Sageretia thea extract
Martinotti et al. Natural compounds and anticancer effects: The whole is greater than the sum of its parts
Adilović et al. Characterization of solvents and optimization of stability and solubility of bioactive compounds used in lymphoma cell culture treatments
Niu et al. Manganese-based nanozymes as broad-spectrum antioxidants against cisplatin-induced skeletal muscle atrophy
KR101000953B1 (en) Non-Repair Extract and Uses
Nikolova et al. Chemoprotective, antioxidant and immunomodulatory in vitro effects of Aronia melanocarpa total extract on laboratory-cultivated normal and malignant cells
Lopes et al. Cytotoxic effects of Vitis labrusca (fox grape) whole juices on human tumor and non-tumor cells, in vitro
Oltulu et al. Effect of L-Dopa on carboplatin induced hepatotoxicity
Ross Neurodegenerative Diseases
Sola et al. Melatonin and Cancer: New Insights
ES2928256T3 (en) Composition comprising 7-hydroxymatairesinol
Darroudi et al. An Updated Overview of the Treatment of Colorectal and Gastric Cancer Using Saffron
Zuvairiya et al. The Oncolytic Effect of Aerva lanata on Osteosarcoma Cell Lines via the Apoptotic Signaling Pathway
Kiburg et al. Effects of the ACTH (4-9) analogue, ORG 2766, on vincristine cytotoxicity in two human lymphoma cell lines, U937 and U715

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE